. 2020 Nov 17;3(11):e2025826. doi: 10.1001/jamanetworkopen.2020.25826

Table 1. Baseline Characteristics of Included Studies.

Study	Phase	Comparison ARI vs control	Patients, No.	Patients, ARI vs control, No.	Cancer status	Age, ARI vs control, median (range), y	Duration of treatment, ARI vs control, median, mo
ARCHES¹³	3 (RCT)	ADT + Enz vs placebo + ADT	1150	574 vs 576	mHSPC	70 (46-92) vs NM	12.8 vs 11.6
STRIVE¹⁴	2 (RDB)	Enz vs Bical	396	198 vs 198	CRPC	72 (46-92) vs 74 (50-91)	14.7 vs 8.4
PREVAIL¹⁵	3 (RDB)	Enz vs placebo	1717	872 vs 845	CRPC	72 (43-93) vs 71 (43-94)	18.2 vs 5.4
PROSPER¹⁶	3 (RDB)	Enz + ADT vs placebo + ADT	1401	933 vs 468	nMCRPC	74 (50-95) vs 73 (53-92)	18.4 vs 11.1
TERRAIN¹⁷	2 (RCT)	Enz vs Bical	375	184 vs 191	CRPC	67 (50-74) vs 66 (48-74)	12.5 vs 6.0
PLATO¹⁸	4 (RDB)	Enz + Abi or Abi	251	126 vs 125	CRPC	72 (67-77) vs 71(65-77)	5.6 vs NM
AFFIRM¹⁹	3 (RDB)	Enz + ADT vs placebo + ADT	1199	800 vs 399	CRPC	NM vs NM	NM vs NM
ENZAMET¹²	3 (RCT)	Enz + ADT vs placebo + ADT	1125	563 vs 562	mHSPC	69 (63-74.5) vs 69 (64-74)	56.2%^a
TITAN²⁰	3(RDB)	Apa + ADT vs placebo + ADT	1052	525 vs 527	mHSPC	69 (45-94) vs 68 (43-90)	20.5 vs 18.3
SPARTAN²¹	3 (RDB)	Apa + ADT vs placebo + ADT	1207	806 vs 401	nMCRPC	74 (48-94) vs 74 (52-97)	60.9%^b
ARAMIS²²	3 (RDB)	Dar + ADT vs placebo + ADT	1509	955 vs 554	nMCRPC	74 (48-95) vs 74 (50-92)	14.8 vs 11

Abbreviations: Abi, abiraterone; ADT, androgen deprivation therapy; Apa, apalutamide; ARI, androgen receptor inhibitor; Bical, bicalutamide; CRPC, castration-resistant prostate cancer; Dar, darolutamide; Enz, enzalutamide; mHSPC, metastatic hormone-sensitive prostate cancer; NM, not mentioned; nMCRPC, nonmetastatic castration-resistant prostate cancer; RCT, randomized clinical trial; RDB, randomized double-blind.

^{^a}

Still receiving treatment at 36 months vs 59.6% still receiving treatment at 36 months.

^{^b}

Still receiving treatment at median follow-up 20.3 months vs 29.9% still receiving therapy at the median follow-up 20.3 months.